Tuesday, 9 September 2014

Dimethyl fumarate (BG-12, Tecfidera) - NICE confirms approval in final guidance

Dimethyl fumarate (BG-12, Tecfidera) will start to be available on the NHS in England and Wales from November following final guidance from NICE (National Institute for Health and Care Excellence).

Dimethyl fumarate is approved as a treatment for adults with active relapsing remitting multiple sclerosis (normally defined as two clinically significant relapses in the previous two years), providing they do not have highly active MS despite treatment or rapidly evolving severe relapsing remitting MS.  Read more here